Biofrontera Inc. Financing Cash Flow
Biofrontera Inc. (BFRI) reported Financing Cash Flow of $10.85 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- Biofrontera Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $2.35M, a 41.98% decline year-over-year.
- Biofrontera Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $0.00.
- Biofrontera Inc. net cash provided by (used in) financing activities for the quarter ending 2024-12-31 was $4.05M, a 39.68% decline year-over-year.
- Biofrontera Inc. net cash provided by (used in) financing activities for the quarter ending 2024-09-30 was -$298.00K, a 150.42% decline year-over-year.
- Biofrontera Inc. net cash provided by (used in) financing activities for fiscal 2025 was $10.85M, a 26.86% decline from fiscal 2024.
- Biofrontera Inc. net cash provided by (used in) financing activities for fiscal 2024 was $14.84M, a 76.38% increase from fiscal 2023.
- Biofrontera Inc. net cash provided by (used in) financing activities for fiscal 2023 was $8.41M, a 40.01% decline from fiscal 2022.
- Biofrontera Inc. net cash provided by (used in) financing activities for fiscal 2022 was $14.02M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2025-12-31 | $2.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $2.35M derived: sum of 2 quarters · filed 2026-03-19 | $10.85M 10-K · filed 2026-03-19 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $8.50M 10-Q · filed 2025-11-12 | ||
| 2025-06-30 | $8.50M 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $4.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $3.75M derived: sum of 2 quarters · filed 2026-03-19 | $9.04M derived: sum of 3 quarters · filed 2026-03-19 | $14.84M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$298.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $4.99M derived: sum of 2 quarters · filed 2025-11-12 | $10.79M 10-Q · filed 2025-11-12 | $17.50M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $5.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $11.08M 10-Q · filed 2025-08-13 | $17.80M derived: sum of 3 quarters · filed 2025-08-13 | $18.39M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $5.80M 10-Q · filed 2025-05-15 | $12.51M derived: sum of 2 quarters · filed 2025-05-15 | $13.10M derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | $6.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $7.30M derived: sum of 2 quarters · filed 2025-03-20 | $8.41M 10-K · filed 2025-03-20 | |
| 2023-09-30 | $591.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.70M 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $1.11M 10-Q · filed 2024-08-14 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $4.63M derived: sum of 2 quarters · filed 2024-03-15 | $14.02M 10-K · filed 2024-03-15 | |
| 2022-09-30 | $4.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $14.02M 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $9.39M 10-Q · filed 2023-08-11 | |||
| 2021-12-31 | $43.83M derived: 8-K 12 month − 10-Q 9 month · filed 2023-10-03 | $43.71M derived: sum of 2 quarters · filed 2023-10-03 | $43.19M 8-K · filed 2023-10-03 | |
| 2021-09-30 | -$121.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$638.00K 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | -$517.00K 10-Q · filed 2022-08-12 | |||
| 2020-12-31 | $4.34M derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-11 | $13.19M 10-K · filed 2022-04-11 | ||
| 2020-09-30 | $8.86M 10-Q · filed 2021-11-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B |